07:00 , Aug 1, 2016 |  BioCentury  |  Product Development

IGF synergy in cancer

Despite a history of failures in targeting the insulin-like growth factor receptor for cancer, Boehringer Ingelheim GmbH and Eli Lilly and Co. have several hypotheses that support greater cell cycle arrest and the potential to...
07:00 , Apr 11, 2011 |  BioCentury  |  Product Development

Ligand approach to IGF

While drug companies have been targeting insulin-like growth factor-1 receptor since it was first implicated in cancer almost two decades ago, the strategy has yet to bear fruit because of tumor resistance and off-target effects....